New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support ...
AgomAb Therapeutics NV ( AGMB) has filed to raise $200 million in development capital in an IPO of its American Depositary Shares representing underlying common shares, according to SEC F-1/A ...
Stay informed on Burn Research advancements at Hamilton Health Sciences and their innovative trial for better burn recovery ...
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programsGelrinC is set to transform cartilage repair market with ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
The Evidence to Recommendations framework ensured that the US vaccine schedule was scientifically sound. Then RFK Jr. abandoned it ...
CANTANHEDE, PORTUGAL, NEW YORK CITY, USA AND DUBLIN, IRELAND, January 12, 2026 /EINPresswire.com/ -- • An early-phase ...
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine ...
Cash-rich Cullinan Therapeutics stock: zipalertinib NDA in Q1 2026 plus CLN-978 and CLN-049 AML catalysts. Read here for more analysis.
Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical ...
Fecal microbiota transplants (FMT) can dramatically improve cancer treatment, suggest two groundbreaking studies published in ...
Worldwide Clinical Trials, a full-service, global CRO headquartered in Research Triangle Park, has entered into a definitive agreement to acquire Wilmington-based Catalyst Clinical Research, a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results